IMPACT OF THE 2017 GOLD STRATEGY ON TIOTROPIUM plus OLODATEROL RESPONSE

被引：0
|
作者：
Langton, D. [1 ,2 ]
Ferguson, G. [3 ]
Voss, F. [4 ]
Maltais, F. [5 ]
Groenke, L. [4 ]
Buhl, R. [6 ]
Watz, H. [7 ]
机构：
[1] Frankston Hosp, Thorac Med, Frankston, Vic, Australia
[2] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia
[3] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[4] Boehringer Ingelheim Corp, Ingelheim, Germany
[5] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] LungClin Grosshansdorf Pulm Res, Pulm Res Inst, Grosshansdorf, Germany
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TO 129
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [1] The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium plus olodaterol trials
    Ferguson, Gary T.
    Watz, Henrik
    Maltais, Francois
    Gronke, Lars
    Voss, Florian
    Buhl, Roland
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [2] Classifying patients as GOLD A-D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium plus olodaterol clinical trials
    Singh, Dave
    Bjermer, Leif
    Abrahams, Roger
    Gronke, Lars
    Voss, Florian
    Ferguson, Gary T.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [3] Clinical improvement by tiotropium plus olodaterol
    Tamura, Tomohiro
    Kagohashi, Katsunori
    Satoh, Hiroaki
    RESPIRATORY MEDICINE, 2017, 125 : 104 - 104
  • [4] Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
    Tamura, Tomohiro
    Satoh, Hiroaki
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2909 - 2909
  • [5] Benefits Of Tiotropium plus Olodaterol Over Tiotropium At Delaying Clinically Significant Events In Patients With COPD Classified As Gold B
    Buhl, R.
    McGarvey, L.
    Korn, S.
    Ferguson, G. T.
    Gronke, L.
    Hallmann, C.
    Vob, F.
    Rabe, K. F.
    Maltais, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [6] Lung-Function Response To Tiotropium plus Olodaterol In Patients With COPD With β-Agonist Reversibility
    Tashkin, D. P.
    Ferguson, G. T.
    Clerisme-Beaty, E.
    Vob, F.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [7] The Impact of GOLD Stage on the Effectiveness of Tiotropium/Olodaterol in Preventing COPD Exacerbations in the DYNAGITO Trial
    Wedzicha, J. A.
    Calverley, P. M.
    Anzueto, A.
    de la Hoz, A.
    Voss, F.
    Rabe, K. F.
    Jenkins, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [8] Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone Reply
    Beeh, Kai-Michael
    Derom, Eric
    Echave-Sustaeta, Jose
    Groenke, Lars
    Hamilton, Alan
    Zhai, Dongmei
    Bjermer, Leif
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2910 - 2910
  • [9] THE IMPACT OF GOLD STAGE ON THE EFFECTIVENESS OF TIOTROPIUM/OLODATEROL IN PREVENTING COPD EXACERBATIONS IN THE DYNAGITO TRIAL
    Wedzicha, J.
    Calverley, P. M. A.
    Anzueto, A. R.
    de la Hoz, A.
    Voss, F.
    Rabe, K. F.
    Jenkins, C.
    THORAX, 2019, 74 : A19 - A20
  • [10] Effect Of Tiotropium plus Olodaterol Therapy On COPD Exacerbations In The Tonado® Studies
    Derom, E.
    Flezar, M.
    Gronke, L.
    Vob, F.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
12345